Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 90,398 | 82,713 | 64,357 | 48,042 | 11,799 |
| Cost of Goods | 8,881 | 9,361 | 7,654 | 5,157 | 1,009 |
| Gross Profit | 81,517 | 73,352 | 56,703 | 42,885 | 10,790 |
| Operating Expenses | 179,180 | 139,249 | 136,398 | 135,334 | 137,538 |
| Operating Income | -96,782 | -65,536 | -79,041 | -92,292 | -126,739 |
| Interest Expense | 12,521 | 14,715 | 8,438 | 0 | 0 |
| Other Income | -14,739 | -18,073 | -20,549 | -17,079 | 1,629 |
| Pre-tax Income | -124,042 | -98,324 | -108,028 | -109,371 | -125,110 |
| Income Tax | 2,832 | 3,920 | 1,755 | 1,449 | 3,374 |
| Net Income Continuous | -126,874 | -102,244 | -109,783 | -110,820 | -128,484 |
| Net Income | $-126,874 | $-102,244 | $-109,783 | $-110,820 | $-128,484 |
| EPS Basic Total Ops | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 |
| EPS Basic Continuous Ops | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 |
| EPS Diluted Total Ops | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 |
| EPS Diluted Continuous Ops | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 |
| EPS Diluted Before Non-Recurring Items | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 |
| EBITDA(a) | $-99,344 | $-65,768 | $-78,615 | $-90,985 | $-125,884 |